6L9.F ViewRay up 2400% to €0.025 on XETRA: high volume flags trader interest

The 6L9.F stock price surged intraday on 11 Feb 2026, climbing to €0.025 after a sharp move of 2400.00%. Trading on XETRA in Germany, volume hit 3,500.00 shares versus an average of 279.00, producing a relative volume of 12.54. This activity reflects concentrated trading interest rather than a broad repricing given the stock’s recent trading range. We track ViewRay, Inc. (6L9.F) because such high-volume spikes can precede short-term volatility or liquidity windows for larger positions.

6L9.F stock intraday price and volume snapshot

ViewRay (6L9.F) opened at €0.001 and printed a day high of €0.025 on XETRA. The intraday volume of 3,500.00 versus avg volume 279.00 shows concentrated orders. The market cap reads €207,228,256.00 and shares outstanding are 8,289,130,240.00, explaining why small blocks move price materially.

6L9.F stock fundamentals and sector context

ViewRay operates in Healthcare, Medical – Devices. Trailing EPS is -0.55 and PE is -0.05, reflecting losses. Price-to-sales is 2.41 and price-to-book is 0.07. The healthcare sector average PE is near 30.90, which highlights ViewRay’s early-stage, loss-making profile versus larger device peers.

6L9.F stock technical and trading signals

Price averages show a 50-day mean €0.31916 and 200-day mean €2.71739, both far above the current print. Short-term traders note the extreme gap between current price €0.025 and moving averages. Relative volume 12.54 increases the risk of rapid reversals and low liquidity at resting bids.

Meyka AI rates 6L9.F with a score out of 100

Meyka AI rates 6L9.F with a score out of 100: 61.47 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 comparison, sector and industry metrics, financial growth, key ratios, forecasts, and analyst sentiment. The score reflects moderate fundamentals, positive cash per share €0.75, but elevated leverage with debt-to-equity 1.05. Grades are informational and not financial advice.

6L9.F stock catalysts and risk factors

Catalysts include MRIdian system sales growth, regulatory approvals, and hospital purchasing cycles. Risks include negative operating margins -1.05, interest coverage -21.18, and very thin intraday liquidity which can widen spreads. Recent price action looks driven by order flow, not by new company announcements.

6L9.F stock trading strategy and analyst view

Active traders may use limit orders and small position sizes to manage spread risk. Institutional investors typically wait for clearer liquidity and earnings updates. Analysts point to long-term medical device demand but flag near-term cash burn and execution risk. Review fundamentals before adding ViewRay to a portfolio.

Final Thoughts

Key takeaways on the 6L9.F stock: intraday action on 11 Feb 2026 pushed the price to €0.025 with 3,500.00 shares traded and a 2400.00% quoted change. The move occurred on XETRA and reflects thin liquidity rather than a structural valuation reset. Meyka AI’s forecast model projects a fair value near €0.065, implying an upside of 160.00% versus the current price. Forecasts are model-based projections and not guarantees. Given negative EPS -0.55, weak profitability metrics, and high relative volume, we view this as a high-volatility trade opportunity for experienced traders, while longer-term investors should seek clearer revenue growth and margin improvement before increasing exposure. For real-time alerts and deeper signals use our AI-powered market analysis on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.